7th RNAi-Based Therapeutics Summit

Conference Details:

7th RNAi-Based Therapeutics Summit

Conference Description:

Discover, Develop and Selectively Deliver Highly Stable and Potent RNAi Therapeutics for Targeted and Effective Gene Silencing in Oncology, Rare, Cardiovascular Disorders and Beyond

The 7th RNAi-Based Therapeutics Summit is the industry’s premier dedicated forum for translating the next wave of siRNA and microRNA drugs from bench to bedside. As the only event uniting the entire RNAi ecosystem from discovery and complex chemistry to clinical development and CMC, this Summit provides an unparalleled platform to tackle the field’s most pressing challenge: delivery beyond the liver. This is your unique opportunity to join 80+ senior leaders from pharma and biotech to gain the data-driven insights and high-value connections needed to overcome stability challenges, de-risk clinical translation, and position your pipeline at the forefront of the next therapeutic revolution.

URL:
Tickets: https://go.evvnt.com/3306289-2?pid=154
Prices:
Drug Developer Pricing – Conference + Workshop Day: USD 4197.00,
Drug Developer Pricing – Conference Only: USD 2999.00,
Academic Pricing – Conference + Workshop Day: USD 3597.00,
Academic Pricing – Conference Only: USD 2599.00,
Service Provider Pricing – Conference + Workshop Day: USD 5097.00,
Service Provider Pricing – Conference Only: USD 3699.00

Speakers: Andrew Coles, Senior Scientist, Abbvie, Muthiah Manoharan, Senior Vice President, Innovation Chemistry, Alnylam Pharmaceuticals, Paul Lawrence, Executive Director – Bioscience Research, Discovery and Scientific Communications, Biocogent, Raj Reddy, CEO, Canary Cure, David Jackson, Chief Executive Officer, Ceria Therapeutics, Claire Zeng, Founder, Chief Technology Officer and Chief Executive Officer, DoriNano, Tere Williams, Chief Executive Officer, DUB Therapeutics, Audrey Bernstein, CSO, DUB Therapeutics, Yaniv Erlich, Chief Executive Officer, Eleven Therapeutics, David Zebrowski, Founder and Chief Executive Officer, GenKardia, Jonathan Hsu, Chief Technology Officer, Gensaic , Uyanga Tsedev, Cheif Executive Officer, Gensaic , Lavi Errison, CEO, Gensaic, Mauricio Garcia-Atance, Program Director, Hanson Wade, Jinggang Ju, Founder and Professor, iNanoRNA Therapeutics, Alfica Sehgal, Chief Scientific Officer, Judo Biosciences, Joe Nabhan, Chief Scientific Officer, K2B Therapeutics, Anthony Saleh, Chief Executive Officer, miRecule, Yacoub Habib, Chief Executive Officer, Ophidion Inc, James Carroll, President and Chief Executive Officer, RNA NanoBiotics, Juhani Lahdenpera, Chief Operating Officer, RNatives, Weimin Wang, Founder and Chief Executive Officer, SanegeneBio, Greta Garrido Hidalgo, CEO and Co-Founder, Sebastian BioPharma, Andre Fraley, Partner, Sunrise Bioventures, Zdravka Medarova, Co-Founder and Chief Technology Officer, TransCode Therapeutics, Julia Alterman, Assistant Professor, UMass Medical School

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Date and Time: 27th January 2026 at 8:00 am to 29th January 2026 at 4:30 pm

Important Dates:

• Conference start date: January 27, 2026
• Conference end date: January 29, 2026

Conference Information:

• Category: Health and Medicine
• Location: United States
• Website: http://go.evvnt.com/3306289-0?pid=154

Contact Information:

• Address: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, Massachusetts, 02114, United States